As the first federally approved psychedelics clinical trial begins in the US, there is broad but not total agreement among official bodies over legalising research into hallucinogenic substances.

The first Phase 1 study into psilocin and psilocybin to be approved by the US Food and Drug Administration (FDA) will examine the physiological and psychological effects of the mushroom-derived compounds when delivered orally and sublingually to healthy adults.

I'm already a subscriber
Author default picture

Freddie Dawson

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization